NDA 021227 · Merck
Cancidas
Caspofungin Acetate · Intravenous
NovelPriority reviewDiscontinuedLast checked: Nov 20, 2026Latest source record: Oct 25, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2001
Jan 26, 2001
Approved uses
7
Original approval plus efficacy supplements
Registered trials
67
24 Phase 3, 3 recruiting
FAERS reports
4,741
4,443 serious, 1,687 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 11, 2024.
CANCIDAS is an echinocandin antifungal indicated in adults and pediatric patients (3 months of age and older) for: Empirical therapy for presumed fungal infections in febrile, neutropenic patients. ( 1 ) Treatment of candidemia and the following Candida infections: intra-abdominal abscesses, peritonitis and pleural space infections. ( 1 ) Treatment of esophageal candidiasis. ( 1 ) Treatment of invasive aspergillosis in patients who are refractory to or intolerant of other therapies. ( 1 ) 1.1 Empirical Therapy for Presumed Fungal Infections in Febrile, Neutropenic Patients CANCIDAS ® is indicated as empirical therapy for presumed fungal infections in febrile, neutropenic adult and pediatric patients (3 months of age and older) [see Clinical Studies (14.1 , 14.5) ]. 1.2 Treatment of Candidemia and Other Candida Infections CANCIDAS is indicated for the treatment of candidemia and the following candida infections: intra-abdominal abscesses, peritonitis, and pleural space infections in adult and pediatric patients (3 months of age and older) [see Clinical Studies (14.2 , 14.5) ]. Limitations of Use: CANCIDAS has not been studied in endocarditis, osteomyelitis, and meningitis due to Candida . 1.3 Treatment of Esophageal Candidiasis CANCIDAS is indicated for the treatment of esophageal candidiasis in adult and pediatric patients (3 months of age and older) [see Clinical Studies (14.3 , 14.5) ]. Limitations of Use: CANCIDAS has not been approved for the treatment of oropharyngeal candidiasis (OPC). In the study that evaluated the efficacy of caspofungin in the treatment of esophageal candidiasis, patients with concomitant OPC had higher relapse rate of the OPC [see Clinical Studies (14.3) ]. 1.4 Treatment of Invasive Aspergillosis in Patients Who Are Refractory to or...
Mechanism: Caspofungin is an echinocandin antifungal drug [see Microbiology (12.4) ].
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 26, 2009 Supplement 23 · Efficacy LabelLetter
- Jul 29, 2008 Supplement 21 · Efficacy · priority review LetterPediatric Written RequestLabel
- Feb 16, 2005 Supplement 15 · Efficacy LetterLabel
- Sep 29, 2004 Supplement 12 · Efficacy LetterLabel
- Jan 7, 2003 Supplement 7 · Efficacy LetterLabel
- Sep 20, 2002 Supplement 1 · Efficacy LetterLabel
- Jan 26, 2001 Original approval · Type 1 - New Molecular Entity · priority review NovelReviewLetterPediatric Medical Review
2 products under this application
- CANCIDAS · CASPOFUNGIN ACETATE 50MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · POWDER, INTRAVENOUS · Discontinued · TE AP
- CANCIDAS · CASPOFUNGIN ACETATE 70MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · POWDER, INTRAVENOUS · Discontinued · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Caspofungin" as an intervention, any sponsor and status, largest first.
- Caspofungin Study for Fungal Infections in Adults in Critical Care SettingsPivotal-lookingTerminated
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00095316 · 1,200 participants (planned) · Start Oct 2004
Drug: Caspofungin · For: Candidiasis
Sites: Birmingham, Alabama; Los Angeles, California; Torrance, California · 26 sites in all
- Caspofungin to Prevent Candidiasis in Adults in Hospital Intensive Care UnitsPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT00099775 · 1,200 participants · Start Dec 2004
Drug: Caspofungin · For: Candidiasis
Sites: Bethesda, Maryland
- Study of Micafungin in Patients With Invasive Candidiasis or CandidemiaPivotal-lookingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT00105144 · 611 participants · Start Sep 2004 · Primary completion Apr 2006
Drug: Micafungin; Caspofungin · For: Candidiasis; Candidemia
Sites: Birmingham, Alabama; Little Rock, Arkansas; Los Angeles, California · 167 sites in all
- Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow TransplantationPivotal-lookingCompleted
Mundipharma Research LimitedIndustry
NCT04368559 · 602 participants · Start May 11, 2020 · Primary completion Jan 29, 2026
Drug: Rezafungin for Injection; Posaconazole and 4 more · For: Candidemia; Mycoses; Fungal Infection and 7 more
Sites: Birmingham, Alabama; Los Angeles, California; Stanford, California · 53 sites in all
- Empirical Versus Preemptive Antifungal TherapyPivotal-lookingCompleted
European Organisation for Research and Treatment of Cancer - EORTCResearch network
NCT01288378 · 556 participants · Start Mar 2012 · Primary completion Apr 4, 2019
Drug: caspofungin acetate · For: Fungal Infection; Leukemia; Myelodysplastic Syndromes
Sites: Bruges, Belgium; Brussels, Belgium; Leuven, Belgium · 16 sites in all
- Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid LeukemiaPivotal-lookingCompleted
Children's Oncology GroupResearch network
NCT01307579 · 517 participants · Start Apr 4, 2011 · Primary completion Jun 30, 2018
Drug: Caspofungin Acetate; Fluconazole · For: Acute Myeloid Leukemia; Adult Acute Monoblastic Leukemia; Adult Acute Monocytic Leukemia and 25 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 179 sites in all
- Trial of Two Dosing Regimens of Micafungin Versus Caspofungin for the Treatment of Esophageal CandidiasisPivotal-lookingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT00665639 · 454 participants · Start Jun 2004 · Primary completion Dec 2004
Drug: micafungin; caspofungin · For: Candidiasis, Oral
Sites: Buenos Aires, Argentina; Córdoba, Argentina; Neuquén, Argentina · 31 sites in all
- Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida InfectionsPivotal-lookingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT00413218 · 450 participants · Start Mar 8, 2007 · Primary completion Mar 3, 2015
Drug: Isavuconazole; Caspofungin and 1 more · For: Candidiasis, Invasive; Candidemia; Mycoses
Sites: Birmingham, Alabama; Palm Desert, California; Sacramento, California · 113 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective684
- off label use252
- death226
- product use in unapproved indication210
- pneumonia203
- pyrexia197
- septic shock197
- sepsis192
- febrile neutropenia170
- multiple organ dysfunction syndrome151
- respiratory failure131
- renal failure129
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 157 |
| 2005 | 138 |
| 2006 | 129 |
| 2007 | 170 |
| 2008 | 143 |
| 2009 | 146 |
| 2010 | 142 |
| 2011 | 186 |
| 2012 | 177 |
| 2013 | 171 |
| 2014 | 221 |
| 2015 | 249 |
| 2016 | 258 |
| 2017 | 314 |
| 2018 | 359 |
| 2019 | 364 |
| 2020 | 282 |
| 2021 | 213 |
| 2022 | 205 |
| 2023 | 187 |
| 2024 | 220 |
| 2025 | 181 |
| 2026 | 129 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Cancidas (Caspofungin Acetate)
2024 spending
$24K
Beneficiaries
n/a
29 claims
Per beneficiary
n/a
$114.67 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $66,887 |
| 2021 | $45,309 |
| 2022 | $71,985 |
| 2023 | $55,072 |
| 2024 | $23,911 |
Part B: Cancidas* (Caspofungin Acetate*) · HCPCS J0637
2024 spending
$15K
Beneficiaries
21
239 claims
Per beneficiary
$710
2024 ASP limit $6.27 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $23,480 |
| 2021 | $54,747 |
| 2022 | $29,172 |
| 2023 | $45,044 |
| 2024 | $14,909 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial.
Thompson GR, Soriano A, Cornely OA, et al. · Lancet 2023 · Randomized Controlled Trial, Multicenter Study
- Histoplasmosis: A systematic review to inform the World Health Organization of a fungal priority pathogens list.
Dao A, Kim HY, Halliday CL, et al. · Med Mycol 2024 · Systematic Review
- Echinocandin antifungal drugs.
Denning DW · Lancet 2003 · Clinical Trial, Comparative Study
- Isavuconazole Versus Caspofungin in the Treatment of Candidemia and Other Invasive Candida Infections: The ACTIVE Trial.
Kullberg BJ, Viscoli C, Pappas PG, et al. · Clin Infect Dis 2019 · Multicenter Study, Randomized Controlled Trial
- Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: pooled data from two prospective randomised controlled trials.
Thompson GR, Soriano A, Honore PM, et al. · Lancet Infect Dis 2024 · Multicenter Study, Randomized Controlled Trial
- Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial.
Thompson GR, Soriano A, Skoutelis A, et al. · Clin Infect Dis 2021 · Clinical Trial, Phase II, Randomized Controlled Trial
Sponsor: Merck
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.